These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells. Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246 [TBL] [Abstract][Full Text] [Related]
3. Pro-apoptotic activity of ruthenium 1-methylimidazole complex on non-small cell lung cancer. Dias JSM; Silva HVR; Ferreira-Silva GÁ; Ionta M; Corrêa CC; Almeida F; Colina-Vegas L; Barbosa MIF; Doriguetto AC J Inorg Biochem; 2018 Oct; 187():1-13. PubMed ID: 30015231 [TBL] [Abstract][Full Text] [Related]
4. Cis-[RuCl(BzCN)(N-N)(P-P)]PF6 complexes: Synthesis and in vitro antitumor activity: (BzCN=benzonitrile; N-N=2,2'-bipyridine; 1,10-phenanthroline; P-P=1,4-bis(diphenylphosphino) butane, 1,2-bis(diphenylphosphino)ethane, or 1,1'-(diphenylphosphino)ferrocene). Pereira Fde C; Lima BA; de Lima AP; Pires WC; Monteiro T; Magalhães LF; Costa W; Graminha AE; Batista AA; Ellena J; Siveira-Lacerda Ede P J Inorg Biochem; 2015 Aug; 149():91-101. PubMed ID: 25873134 [TBL] [Abstract][Full Text] [Related]
5. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features. Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963 [TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity and mechanism of apoptosis of A549 induced by ruthenium complex. Sun D; Mou Z; Li N; Zhang W; Wang Y; Yang E; Wang W J Biol Inorg Chem; 2016 Dec; 21(8):945-956. PubMed ID: 27620172 [TBL] [Abstract][Full Text] [Related]
7. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents. Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192 [TBL] [Abstract][Full Text] [Related]
8. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors. de Camargo MS; De Grandis RA; da Silva MM; da Silva PB; Santoni MM; Eismann CE; Menegário AA; Cominetti MR; Zanelli CF; Pavan FR; Batista AA Biometals; 2019 Feb; 32(1):89-100. PubMed ID: 30506342 [TBL] [Abstract][Full Text] [Related]
9. Non-mutagenic Ru(ii) complexes: cytotoxicity, topoisomerase IB inhibition, DNA and HSA binding. da Silva MM; de Camargo MS; Correa RS; Castelli S; De Grandis RA; Takarada JE; Varanda EA; Castellano EE; Deflon VM; Cominetti MR; Desideri A; Batista AA Dalton Trans; 2019 Oct; 48(39):14885-14897. PubMed ID: 31555783 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antitumor activity of a novel carbonyl ruthenium compound, the ct-[RuCl(CO)(dppb)(bipy)]PF-6[dppb=1,4-bis(diphenylphosphine)butane and bipy=2,2'-bipyridine]. Carnizello AP; Barbosa MI; Martins M; Ferreira NH; Oliveira PF; Magalhães GM; Batista AA; Tavares DC J Inorg Biochem; 2016 Nov; 164():42-48. PubMed ID: 27613330 [TBL] [Abstract][Full Text] [Related]
12. Ru(II)-Based Amino Acid Complexes Show Promise for Leukemia Treatment: Cytotoxicity and Some Light on their Mechanism of Action. de Lima AP; Almeida MAP; Mello-Andrade F; de Castro Pereira F; Pires WC; Abreu DC; de Souza Velozo-Sá V; Batista AA; de Paula Silveira-Lacerda E Biol Trace Elem Res; 2020 Sep; 197(1):123-131. PubMed ID: 31773484 [TBL] [Abstract][Full Text] [Related]
13. cis-[RuCl(BzCN)(bipy)(dppe)]PF6 induces anti-angiogenesis and apoptosis by a mechanism of caspase-dependent involving DNA damage, PARP activation, and Tp53 induction in Ehrlich tumor cells. Magalhães LF; Mello-Andrade F; Pires WC; Silva HD; da Silva PFF; Macedo LM; Henrique de Castro C; Carneiro CC; Cardoso CG; de Melo Reis PR; Camargo de Oliveira L; Caetano RR; Batista AA; Silveira-Lacerda EP Chem Biol Interact; 2017 Dec; 278():101-113. PubMed ID: 28935426 [TBL] [Abstract][Full Text] [Related]
14. Imine-N-Heterocyclic Carbenes as Versatile Ligands in Ruthenium(II) p-Cymene Anticancer Complexes: A Structure-Activity Relationship Study. Yang Y; Guo L; Tian Z; Liu X; Gong Y; Zheng H; Ge X; Liu Z Chem Asian J; 2018 Oct; 13(19):2923-2933. PubMed ID: 30101417 [TBL] [Abstract][Full Text] [Related]
15. Ruthenium (II) complex cis-[Ru Costa MS; Gonçalves YG; Borges BC; Silva MJB; Amstalden MK; Costa TR; Antunes LMG; Rodrigues RS; Rodrigues VM; de Faria Franca E; Zoia MAP; de Araújo TG; Goulart LR; Von Poelhsitz G; Yoneyama KAG Sci Rep; 2020 Sep; 10(1):15410. PubMed ID: 32958783 [TBL] [Abstract][Full Text] [Related]
16. Anticancer activity and mechanism of bis-pyrimidine based dimetallic Ru(II)(η Bhatti MZ; Ali A; Duong HQ; Chen J; Rahman FU J Inorg Biochem; 2019 May; 194():52-64. PubMed ID: 30831390 [TBL] [Abstract][Full Text] [Related]
17. Heterobimetallic Ru(ii)/Fe(ii) complexes as potent anticancer agents against breast cancer cells, inducing apoptosis through multiple targets. Guedes APM; Mello-Andrade F; Pires WC; de Sousa MAM; da Silva PFF; de Camargo MS; Gemeiner H; Amauri MA; Gomes Cardoso C; de Melo Reis PR; Silveira-Lacerda EP; Batista AA Metallomics; 2020 Apr; 12(4):547-561. PubMed ID: 32108850 [TBL] [Abstract][Full Text] [Related]